Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Feb 12, 2025
– Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million
– Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in Q1 2025, followed by MAA in Q3 2025
Read more at globenewswire.com
